Antiviral activity of meliacine on the replication of a thymidine kinase-deficient mutant of Herpes simplex virus type 1 alone and in combination with acyclovir

International Journal of Antimicrobial Agents

Volumn 9, Issue 1, 1997, Pages 49-55

  Barquero, Andrea A ^a   Alché, Laura E ^a   Coto, Celia E ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Acyclovir; Drug combination; Herpes simplex virus type 12; Meliacine

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; MELIA AZEDARACH EXTRACT; MELIACINE; PEPTIDE; PLANT EXTRACT; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ISOLATION; DRUG POTENTIATION; ENZYME DEFICIENCY; HERPES SIMPLEX VIRUS 1; IMMUNOFLUORESCENCE TEST; NONHUMAN; PLANT LEAF; PRIORITY JOURNAL; VERO CELL; VIRUS MUTANT; VIRUS REPLICATION;

EID: 0030740769     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(97)00023-X     Document Type: Article

References (18)

1. Stewart JA, Reef SE, Pellet PE, Corey L, Whitley RJ. Herpesvirus infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1995;21:S114-20.
2. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc Natl Acad Sci USA 1977;74:5716-20.
3. Whitley RJ, Gnann JW Jr. Antiviral Therapy. In: Roizman B, Whitley RJ, Lopez C, editors. The Human Herpesviruses. New York: Raven Press, 1993;329-348.
4. Crumpacker CS, Schnipper LE, Marlowe SI, Kowalsky PN, Hershey BJ, Levin MJ. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med 1982;306:343-6.
5. Erlich KS, Millis J, Chatis P, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989;320:293-6.
6. Birch CJ, Tachediian G, Doherty RR, Hayes K, Gust ID. Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome. J Infect Dis 1990;162:731-4.
7. Villamil SM, Alche LE, Coto CE. Inhibition of herpes simplex virus type 1 multiplication by meliacine, a peptide of plant origin. Antiviral Chem Chemother 1995;6:239-44.
8. Andrei GM, Couto AS, Lederkremer RM, Coto CE. Purification and partial characterization of an antiviral active peptide from Melia azedarach L. Antiviral Chem Chemother 1994;5:105-10.
9. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
10. Chou T-C, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
11. Suhnel J. Evaluation of synergism or antagonism for the combined action of antiviral agents. Antiviral Res 1990;13:23-40.
12. Silber AM, Candurra NA, Damonte EB. The effects of oligosaccharide trimming inhibitors on glycoprotein expression and infectivity of Junin virus. FEMS Microbiol Lett 1993;109:39-44.
13. Hartshorn KL, Vogt MW, Chou T-C, et al. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha-A interferon. Antimicrob Agents Chemother 1987;31:168-72.
14. Antonelli G, Dianzani F, Bellarosa D, Turriziani O, Riva E, Gentile A. Drug combination of AZT and ddI: synergism. of action and prevention of appearance of AZT-resistance. Antiviral Chem Chemother 1994;5:51-5.
15. Hartshorn KL, Sandstrom EG, Neumeyer D, et al. Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon. Antimicrob Agents Chemother 1986;30:189-91.
16. Schinazi RF, Chou T-C, Scott RT, Yao X, Nahmias AJ. Delayed treatment with herpes simplex virus and application of the median effect method of analysis. Antimicrob Agents Chemother 1986;30:491-8.
17. Prichard MN, Shipman CH Jr. A three-dimensional model to analyze drug-drug interactions. Antiviral Res 1990;14:181-206.
18. Johnson VA, Merrill DP, Videler JA, et al. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-α A inhibit replication of zidovudineresistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis 1991;164:646-55.